The Effect of Human Albumin on Coagulation Competence and Hemorrhage
Primary Purpose
Hemorrhage; Complicating Delivery, Coagulation Defect
Status
Unknown status
Phase
Phase 4
Locations
Denmark
Study Type
Interventional
Intervention
5% Human Albumin " Behring"
Lactated Ringer
Sponsored by
About this trial
This is an interventional treatment trial for Hemorrhage; Complicating Delivery, Coagulation Defect
Eligibility Criteria
Inclusion Criteria:
- Patient more than 18 years old
- Indication for elective post-renal operation including cystectomy
- Patient without anticoagulative, acetylsalicylic acid or nonsteroidal antiinflammatory drug
treatment for the last 5 days
Exclusion Criteria:
- Intracerebral bleeding, manifest cardiac insufficient, renal insufficient demanding dialysis, hepatic or coagulation diseases
- Pregnant or nursing
- Allergic to Human Albumin
- Disturbance in electrolytes
- Patient under committee
- Patient joining another trial interfering the actual trial
Sites / Locations
- Rigshospitalet
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Placebo Comparator
Arm Label
Human Albumin " Behring"
Lactated Ringer
Arm Description
Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
Outcomes
Primary Outcome Measures
Measurement of coagulation during surgery and in the recovery room
Changes in fibrinogen, platelets, hemoglobin, alpha angle and maximum amplitude
Secondary Outcome Measures
Measurement of postoperative surgical complications
Numbers of participants with site infection, postoperative bleeding and leak requiring reoperation
Measurement of hemorrhage and use of blood products during anesthesia and in the recovery room
Volume of lost blood during anesthesia, infusion of blood products, lactated Ringer's and Human Albumin
Full Information
NCT ID
NCT02270723
First Posted
September 27, 2014
Last Updated
October 17, 2014
Sponsor
Kirsten Cleemann Rasmussen
1. Study Identification
Unique Protocol Identification Number
NCT02270723
Brief Title
The Effect of Human Albumin on Coagulation Competence and Hemorrhage
Official Title
Effect of Colloid Versus Crystalloid on Coagulation in Elective Urological Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
October 2014
Overall Recruitment Status
Unknown status
Study Start Date
August 2014 (undefined)
Primary Completion Date
August 2015 (Anticipated)
Study Completion Date
November 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Kirsten Cleemann Rasmussen
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
In a randomized clinical trial, the purpose is to investigate if perioperative coagulation and hemorrhage is influenced by colloid or crystalloid.
Detailed Description
5% Human Albumin is used for fluid therapy during surgery. This study evaluate whether affected coagulation competence induced by Human Albumin leads to a significant perioperative blood loss when compared to administration of lactated Ringer´s solution.
Data are gathered by the investigators, analysed by the sponsor, and remain confidential throughout the process. The investigators shall be involved in all stages of the study development and vouch for the completeness and accuracy of the data. No third part shall influence the protocol, trial conduct, data analysis, or reporting.
The investigators will include 40 patients undergoing cystectomy. Heart rate, mean arterial pressure, cardiac output are measured after induction of anaesthesia and insertion of the arterial catheter (T0), after establishing normovolaemia but before surgery (T1), after resection of the urinary bladder (T2), at the end of the surgery (T3), and two hours thereafter in the recovery room (T4).
Arterial blood is drawn for whole blood viscoelastic haemostatic assays to record clot initiation (R-Time), formation (Maximal Amplitude, MA), alpha angle(α) and lysis (Ly30) depicting haemostatic competence (thrombelastography). The investigators analyze blood for haemoglobin, creatinine, platelets, and fibrinogen. Furthermore, blood is drawn from the central venous catheter for lactate and blood gas variables (ABL 825, Radiometer, Copenhagen, Denmark). To avoid excessive administration of Human Albumin, patients receive lactated Ringer´s solution if considered needed after the infusion 25 mL/kg of the allocated fluid (non-study fluid).
The fluid balance inclusive the blood loss was calculated after cystectomy, at the end of surgery, and two hours thereafter. The investigators register complications postoperatively inclusive hospital stay until discharge.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemorrhage; Complicating Delivery, Coagulation Defect
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
40 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Human Albumin " Behring"
Arm Type
Active Comparator
Arm Description
Infusion of 5% Human Albumine, maximal 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
Arm Title
Lactated Ringer
Arm Type
Placebo Comparator
Arm Description
Infusion of Lactated Ringer solution 25 ml/kg, is administered intravenously during anaesthesia, duration up to 6 hours
Intervention Type
Drug
Intervention Name(s)
5% Human Albumin " Behring"
Other Intervention Name(s)
Human Albumin
Intervention Description
Intravenous infusion of 5% Human Albumin during major surgery
Intervention Type
Drug
Intervention Name(s)
Lactated Ringer
Other Intervention Name(s)
Ringer
Intervention Description
Intravenous infusion of Lactated Ringer during major surgery
Primary Outcome Measure Information:
Title
Measurement of coagulation during surgery and in the recovery room
Description
Changes in fibrinogen, platelets, hemoglobin, alpha angle and maximum amplitude
Time Frame
up to 1 day after surgery
Secondary Outcome Measure Information:
Title
Measurement of postoperative surgical complications
Description
Numbers of participants with site infection, postoperative bleeding and leak requiring reoperation
Time Frame
From date of operation up to 1 months postoperatvely
Title
Measurement of hemorrhage and use of blood products during anesthesia and in the recovery room
Description
Volume of lost blood during anesthesia, infusion of blood products, lactated Ringer's and Human Albumin
Time Frame
up to 1 day after surgery
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient more than 18 years old
Indication for elective post-renal operation including cystectomy
Patient without anticoagulative, acetylsalicylic acid or nonsteroidal antiinflammatory drug
treatment for the last 5 days
Exclusion Criteria:
Intracerebral bleeding, manifest cardiac insufficient, renal insufficient demanding dialysis, hepatic or coagulation diseases
Pregnant or nursing
Allergic to Human Albumin
Disturbance in electrolytes
Patient under committee
Patient joining another trial interfering the actual trial
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Niels H Secher, MD PHD Prof
Organizational Affiliation
Rigshospitalet, University of Copenhagen
Official's Role
Study Chair
Facility Information:
Facility Name
Rigshospitalet
City
Copenhagen
ZIP/Postal Code
2100
Country
Denmark
12. IPD Sharing Statement
Citations:
PubMed Identifier
26945358
Citation
Rasmussen KC, Hojskov M, Johansson PI, Kridina I, Kistorp T, Salling L, Nielsen HB, Ruhnau B, Pedersen T, Secher NH. Impact of Albumin on Coagulation Competence and Hemorrhage During Major Surgery: A Randomized Controlled Trial. Medicine (Baltimore). 2016 Mar;95(9):e2720. doi: 10.1097/MD.0000000000002720.
Results Reference
derived
Learn more about this trial
The Effect of Human Albumin on Coagulation Competence and Hemorrhage
We'll reach out to this number within 24 hrs